P11.17 Splicing dysregulation drives glioblastoma malignancy: SRSF3 as a potential therapeutic target to impair glioblastoma progression

Glioblastomas (GBMs) remain the deadliest human brain tumors, with poor prognosis despite years of research. Currently, standard therapeutic strategies to treat GBM are not efficient and common survival from diagnosis is ~12–16 months. Thus, identification of new diagnostic/prognostic/therapeutic to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Fuentes-Fayos, A C, Vázquez-Borrego, M C, Jiménez-Vacas, J M, Bejarano, L, Blanco-Acevedo, C, Sánchez-Sánchez, R, Solivera, J, Blasco, M A, Castaño, J P, Luque, R M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Poster Presentations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796159/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.163
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller